NCT03799770

Brief Summary

This is a diagnostic test accuracy study. The investigators measure optic nerve sheath diameter (ONSD) by ultrasound on the eye during living donor liver transplantation operation at 5 minutes after reperfusion to predict the occurrence of early tacrolimus neurotoxicity after liver transplantation. We measured the ONSD at 4 timings: (T1) Post induction and before surgical incision, (T2) Portal vein clamping, (T3) 5 minutes after reperfusion, and (T4) 30 min after reperfusion.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2019

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

January 6, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 10, 2019

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 23, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 23, 2021

Completed
Last Updated

April 12, 2022

Status Verified

April 1, 2022

Enrollment Period

2.2 years

First QC Date

January 6, 2019

Last Update Submit

April 7, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Early tacrolimus neurotoxicity

    definition that will be considered when neurological events (visual disturbance, altered level of consciousness, confusion, psychosis, seizure, encephalopathy, tremors and/or coma or change in the pattern of the preexisting cirrhotic neurological changes ) appeared in the absence of central pontine myelinolysis, central nervous system infection, stroke, or hemorrhage within the first 4 weeks after LT and symptoms improved after dose modification of CNI therapy

    28 days after transplantation

Secondary Outcomes (4)

  • Time and presentation of neurotoxicity

    28 days after transplantation

  • Intensive Care Unit stay

    until discharge from ICU for 1 year

  • Hospital Length of stay

    until discharge from the hospital for 1 year

  • Mortality

    three months after transplant

Interventions

Patients were placed in the supine position with their eyes closed, and a thick gel layer was applied to the closed upper eyelid. The 7.5-MHz linear probe was placed on the gel without excessive pressure and adjusted to the proper angle for displaying the entry of the optic nerve into the globe. The intensity of the ultrasound was adjusted to display optimal contrast between the retrobulbar echogenic fat tissue and the vertical hypoechoic band. An ultrasound beam was focused on the retrobulbar area using the lowest possible acoustic power that could measure ONSD. The ONSD was measured 3 mm behind the optic disc. Measurements were performed in the transverse and sagittal planes of both eyes, and the final ONSD value was calculated by average 4 measured values. We measured the ONSD at 4 timings: (T1) Post induction and before surgical incision, (T2) Portal vein clamping, (T3) 5 minutes after reperfusion, and (T4) 30 min after reperfusion.

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Adult (\>= 18 years) recipients undergoing living donor liver transplantation

You may qualify if:

  • All adult patients of both sex undergoing living donor liver transplantation operation

You may not qualify if:

  • History of optic neuritis
  • History of Arachnoid cyst of the optic nerve.
  • History of eye trauma
  • History of optic nerve trauma.
  • Familial amylodotic polyneuropathy
  • Wilson disease.
  • Patient planned to use immunosuppression regimen other than tacrolimus.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gastroenerology Surgical Center - Liver transplantation program

Al Mansurah, Dakahlia Governorate, 35516, Egypt

Location

Related Publications (1)

  • Elsedeiq M, Abdelkhalek M, Abozeid KM, Habl MS, Elmorshedi MA, Yassen AM, Emara MM. Intraoperative Optic Nerve Sheath Diameter as a Predictor of Early Tacrolimus Neurotoxicity after Living Donor Liver Transplantation. Anaesth Crit Care Pain Med. 2023 Feb;42(1):101178. doi: 10.1016/j.accpm.2022.101178. Epub 2022 Nov 25.

Study Officials

  • Mahmoud M. Elsedeiq, MD

    Lecturer of anaesthesia and intensive care

    PRINCIPAL INVESTIGATOR
  • Amr M. Yassin, MD

    professor of anaesthesia and surgical intensive care

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
professor of anaesthesia and surgical intensive care

Study Record Dates

First Submitted

January 6, 2019

First Posted

January 10, 2019

Study Start

January 1, 2019

Primary Completion

March 23, 2021

Study Completion

March 23, 2021

Last Updated

April 12, 2022

Record last verified: 2022-04

Locations